Treatment of osteoarthritis with Pycnogenol®. The SVOS (San Valentino osteo-arthrosis study). evaluation of signs, symptoms, physical performance and vascular aspects
Article first published online: 2 APR 2008
Copyright © 2008 John Wiley & Sons, Ltd.
Volume 22, Issue 4, pages 518–523, April 2008
How to Cite
Belcaro, G., Cesarone, M. R., Errichi, S., Zulli, C., Errichi, B. M., Vinciguerra, G., Ledda, A., Renzo, A. D., Stuard, S., Dugall, M., Pellegrini, L., Errichi, S., Gizzi, G., Ippolito, E., Ricci, A., Cacchio, M., Cipollone, G., Ruffini, I., Fano, F., Hosoi, M. and Rohdewald, P. (2008), Treatment of osteoarthritis with Pycnogenol®. The SVOS (San Valentino osteo-arthrosis study). evaluation of signs, symptoms, physical performance and vascular aspects. Phytother. Res., 22: 518–523. doi: 10.1002/ptr.2376
- Issue published online: 2 APR 2008
- Article first published online: 2 APR 2008
- Manuscript Accepted: 4 SEP 2007
- Manuscript Received: 16 AUG 2007
- Manuscript Revised: 28 MAR 2007
- antiinflammatory agents;
- noninvasive investigations;
- muscular performance;
The aim of this double-blind, placebo-controlled study was to evaluate the efficacy of 100 mg Pycnogenol® daily (oral capsules) in a 3 month study in patients with osteoarthritis (OA). OA symptoms were evaluated by WOMAC scores, mobility by recording their walking performance (treadmill). Treatment (77 patients) and placebo group (79) were comparable for age, sex distribution, WOMAC scores, walking distances and use of antiinflammatory drugs. The global WOMAC score decreased by 56% (p < 0.05) in the treatment group versus 9.6% in the placebo group. Walking distance in the treadmill test was prolonged from 68 m at the start to 198 m after 3 months treatment (p < 0.05), under placebo, from 65 m to 88 m (NS). The use of drugs decreased by 58% in the treatment group (p < 0.05) versus 1% under placebo. Gastrointestinal complications decreased by 63% in the treatment group, but only 3% under placebo. Overall, treatment costs were reduced significantly compared with placebo. Foot edema was present in 76% of the patients of the treatment group at inclusion and in 79% of the controls. After 3 months edema decreased in 79% of Pycnogenol patients (p < 0.05) vs 1% in controls. In conclusion, Pycnogenol offers an option for reduction of treatment costs and side effects by sparing antiinflammatory drugs. Copyright © 2008 John Wiley & Sons, Ltd.